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LPS preconditioning redirects TLR signaling
following stroke: TRIF-IRF3 plays a seminal role in
mediating tolerance to ischemic injury




Background: Toll-like receptor 4 (TLR4) is activated in response to cerebral ischemia leading to substantial
brain damage. In contrast, mild activation of TLR4 by preconditioning with low dose exposure to
lipopolysaccharide (LPS) prior to cerebral ischemia dramatically improves outcome by reprogramming the
signaling response to injury. This suggests that TLR4 signaling can be altered to induce an endogenously
neuroprotective phenotype. However, the TLR4 signaling events involved in this neuroprotective response are
poorly understood. Here we define several molecular mediators of the primary signaling cascades induced by
LPS preconditioning that give rise to the reprogrammed response to cerebral ischemia and confer the
neuroprotective phenotype.
Methods: C57BL6 mice were preconditioned with low dose LPS prior to transient middle cerebral artery occlusion
(MCAO). Cortical tissue and blood were collected following MCAO. Microarray and qtPCR were performed to
analyze gene expression associated with TLR4 signaling. EMSA and DNA binding ELISA were used to evaluate
NFB and IRF3 activity. Protein expression was determined using Western blot or ELISA. MyD88-/- and TRIF-/- mice
were utilized to evaluate signaling in LPS preconditioning-induced neuroprotection.
Results: Gene expression analyses revealed that LPS preconditioning resulted in a marked upregulation of anti-
inflammatory/type I IFN-associated genes following ischemia while pro-inflammatory genes induced following
ischemia were present but not differentially modulated by LPS. Interestingly, although expression of pro-
inflammatory genes was observed, there was decreased activity of NFB p65 and increased presence of NFB
inhibitors, including Ship1, Tollip, and p105, in LPS-preconditioned mice following stroke. In contrast, IRF3 activity
was enhanced in LPS-preconditioned mice following stroke. TRIF and MyD88 deficient mice revealed that
neuroprotection induced by LPS depends on TLR4 signaling via TRIF, which activates IRF3, but does not depend
on MyD88 signaling.
Conclusion: Our results characterize several critical mediators of the TLR4 signaling events associated with
neuroprotection. LPS preconditioning redirects TLR4 signaling in response to stroke through suppression of NFB
activity, enhanced IRF3 activity, and increased anti-inflammatory/type I IFN gene expression. Interestingly, this
protective phenotype does not require the suppression of pro-inflammatory mediators. Furthermore, our results
highlight a critical role for TRIF-IRF3 signaling as the governing mechanism in the neuroprotective response to
stroke.
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Stroke is one of the leading causes of death and the
leading cause of morbidity in the United States [1]. The
inflammatory response to stroke substantially exacer-
bates ischemic damage. The acute activation of the
NFB transcription factor has been linked to the inflam-
matory response to stroke [2] and suppression of NFB
activity following stroke has been found to reduce
damage [3]. NFB activation can lead to the dramatic
upregulation of inflammatory molecules and cytokines
including TNFa,I L 6 ,I L 1 b, and COX2 [2]. The source
of these inflammatory molecules in the acute response
to stroke appears to stem from the cells of the central
nervous system (CNS), including neurons and glial cells
[2]. The cells in the CNS play a particularly dominant
role early in the response to ischemia because infiltrat-
ing leukocytes do not appear in substantial numbers in
the brain until 24 hr following injury [4]. Stroke also
induces an acute inflammatory response in the circulat-
ing blood. Inflammatory cytokine and chemokine levels,
including IL6, IL1b,M C P - 1a n dT N F a are elevated in
the circulation following stroke [5]. This suggests there
is an intimate relationship between responses in the
brain and blood following stroke–responses that result
in increased inflammation.
Toll-like receptors (TLRs), traditionally considered
innate immune receptors, signal through the adaptor
proteins MyD88 and TRIF to activate NFBa n di n t e r -
feron regulatory factors (IRFs). It has been shown
recently that TLRs become activated in response to
endogenous ligands, known as damage associated mole-
cular patterns (DAMPs), released during injury. Interest-
ingly, animals deficient in TLR2 or TLR4 have
significantly reduced infarct sizes in several models of
stroke [6-11]. This suggests that TLR2 and TLR4 activa-
tion in response to ischemic injury exacerbates damage.
In addition, a recent investigation in humans showed
that the inflammatory responses to stroke in the blood
were linked to increased TLR2 and TLR4 expression on
hematopoetic cells and associated with worse outcome
in stroke [12]. The detrimental effect of TLR signaling is
associated with the pathways that lead to NFBa c t i v a -
tion and pro-inflammatory responses. In contrast, TLR
signaling pathways that activate IRFs can induce anti-
inflammatory mediators and type I IFNs that have been
associated with neuroprotection [13,14]. Thus, in TLR
signaling there is a fine balance between pathways lead-
ing to injury or protection.
TLR ligands have been a major source of interest as
preconditioning agents for prophylactic therapy against
ischemic injury. Such therapies would target a popula-
tion of patients that are at risk of ischemia in the setting
of surgery [15-18]. Preconditioning with low doses of
ligands for TLR2, TLR4, and TLR9 all successfully
reduce infarct size in experimental models of stroke
[19-21], including a recent study showing that a TLR9
ligand is neuroprotective in a nonhuman primate model
of stroke [22]. Emerging evidence suggests that TLR-
induced neuroprotection occurs by reprogramming the
genomic response to the DAMPs, which are produced
in response to ischemic injury. In this reprogrammed
state, the resultant pathway activation of TLR4 signaling
preferentially leads to IRF-mediated gene expression
[13,14]. However, whether TLR preconditioning affects
NFB activity and pro-inflammatory signaling is
unknown. As yet, a complete analysis of the characteris-
tic TLR signaling responses to stroke following precon-
ditioning has not been reported. The objective of this
study is to utilize LPS preconditioning followed by tran-
sient middle cerebral artery occlusion (MCAO) to eluci-
date the reprogrammed TLR response to stroke and to
determine the major pathways involved in producing
the neuroprotective phenotype.
Here we show that preconditioning against ischemia
using LPS leads to suppressed NFB activity–although
pro-inflammatory gene expression does not appear to be
attenuated. We also demonstrate that LPS-precondi-
tioned mice have enhanced IRF3 activity and anti-
inflammatory/type I IFN gene expression in the
ischemic brain. This expression pattern was recapitu-
lated in the blood where plasma levels of pro-inflamma-
tory cytokine proteins were comparable in LPS-
preconditioned and control mice while IRF-associated
proteins were enhanced in LPS preconditioned mice. To
our knowledge, we provide the first evidence that pro-
tection due to LPS preconditioning stems from TRIF
signaling, the cascade that is associated with IRF3 acti-
vation, and is independent of MyD88 signaling. These
molecular features suggest that, following stroke, signal-
ing is directed away from NFB activity and towards a
dominant TRIF-IRF3 response. Understanding the endo-
genous signaling events that promote protection against
ischemic injury is integral to the identification and
development of novel stroke therapeutics. In particular,
the evidence presented here further highlights a key role
for IRF3 activity in the protective response to stroke.
Methods
Animals
C57Bl/6J mice (male, 8-12 weeks) were purchased from
Jackson Laboratories (West Sacramento, CA). C57Bl/6J-
Ticam1
LPS2/J (TRIF-/-) mice were also obtained from
Jackson Laboratories. MyD88-/- mice were a kind gift of
Dr. Shizuo Akira (Osaka University, Osaka Japan) and
were bred in our facility. All mice were housed in an
American Association for Laboratory Animal Care-
approved facility. Procedures were conducted according
to Oregon Health & Science University, Institutional
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tutes of Health guidelines.
LPS treatment
Mice were preconditioned with LPS (0.2 or 0.8 mg/kg,
Escherichia coli serotype 0111:B4; Sigma) or saline by
one subcutaneous injection, unless otherwise indicated,
72 hr prior to MCAO. Each new lot of LPS was titrated
for the optimal dose that confers neuroprotection. No
differences were observed in the genomic responses to
LPS for each dose used and route of administration
(subcutaneous or intraperitoneal, data not shown).
Middle Cerebral Artery Occlusion (MCAO)
Mice were anesthetized with isoflurane (1.5-2%) and
subjected to MCAO using the monofilament suture
method described previously [23]. Briefly, a silicone-
coated 7-0 monofilament nylon surgical suture was
threaded through the external carotid artery to the
internal carotid artery to block the middle cerebral
artery, and maintained intraluminally for 40 to 60 min.
The suture was then removed to restore blood flow.
The duration of occlusion was optimized based on the
specific surgeon who performed the MCAO to yield
comparable infarct sizes in the saline treated control
animals (~35-40%). The selected duration of MCAO
was held constant within experiments. Cerebral blood
flow (CBF) was monitored throughout surgery by laser
doppler flowmetry. Any mouse that did not maintain a
CBF during occlusion of <25% of baseline was excluded
from the study. The reduction of CBF was comparable
in LPS and saline preconditioned mice in response to
MCAO. Body temperature was monitored and main-
tained at 37°C with a thermostat-controlled heating pad.
Infarct measurements were made using triphenyltetrazo-
lium chloride (TTC) staining of 1 mm coronal brain
sections.
Tissue collection
Under deep isoflurane anesthesia, approximately ~0.5-
1.0 ml of blood was collected via cardiac puncture in a
heparinized syringe. Subsequently, the mice were per-
fused with heparinized (2 U/ml) saline followed by rapid
removal of the brain. The olfactory bulbs were removed
and the first 4 mm of tissue was collected beginning at
the rostral end. The striatum was dissected and removed
and the remaining cortex was utilized for RNA isolation
or protein extraction. The collected blood was centri-
fuged at 5000 × g for 20 min to obtain plasma that was
stored at -80°C.
Genomic profiling of TLR associated mediators
For the genes displayed in Figure 1, the transcript
expression levels were determined as previously
described from our microarray experiments examining
the brain cortical response to stroke and 3 different
Figure 1 Microarray analysis of anti-inflammatory/type I IFN and pro-inflammatory gene expression. Microarray analysis revealed
enhanced anti-inflammatory/type I IFN and comparable pro-inflammatory gene expression profiles in the brain of LPS-preconditioned (0.2 mg/
kg, intraperitoneal injection) mice following 45 min MCAO. Heatmap representing level of gene expression immediately prior to (0 hr) MCAO
and 3 and 24 hr post MCAO; n = 4/treatment/timepoint. Lt. Select anti-inflammatory/type I IFN genes. Rt. Select pro-inflammatory genes. Color
scale from green to red represents relative decreased or increased gene expression levels, respectively.
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lated from the ipsilateral cortex (n = 4 mice/treatment/
timepoint), using the Qiagen Rneasy Lipid Mini Kit
(Qiagen). Microarray assays were performed in the Affy-
metrix Microarray Core of the Oregon Health & Science
University Gene Microarray Shared Resource. RNA
samples were labeled using the NuGEN Ovation Biotin
RNA Amplification and Labeling System_V1. Hybridiza-
tion was performed as described in the Affymetrix tech-
nical manual (Affymetrix) with modification as
recommended for the Ovation labeling protocol
(NuGEN Technologies). Labeled cRNA target was qual-
ity-checked based on yield and size distribution. Qual-
ity-tested samples were hybridized to the MOE430 2.0
array. The array image was processed with Affymetrix
GeneChip Operating Software (GCOS). Affymetrix CEL
files were then uploaded into GeneSifter (http://www.
genesifter.net) and normalized using RMA.
RNA isolation, Reverse Transcription, and qtPCR
RNA was isolated from cortical tissue 72 hr post injec-
tion or from ipsilateral cortical tissue at 3 or 24 hr fol-
lowing MCAO (n ≥ 4 mice/treatment/timepoint) using
a Lipid Mini RNA isolation kit (Qiagen). Reverse tran-
scription was performed on 2 μgo fR N Au s i n gO m n i s -
cript (Qiagen). Quantitative PCR was performed using
Taqman Gene Expression Assays (Applied Biosystems)
for each gene of interest on an ABI Prism 7700. Results
were normalized to b-Actin expression and analyzed
relative to their saline preconditioned counterparts. The
relative quantification of the gene of interest was deter-
mined using the comparative CT method (2
-DDCt).
Western Blot
Protein extraction was performed as described pre-
viously [24] with some modifications. Briefly, tissue sam-
ples (n ≥ 4 mice/treatment/timepoint) were dissected
from the ipsilateral cortex and lysed in a buffer contain-
ing a protease inhibitor cocktail (Roche). Protein con-
centrations were determined using the BCA method
(Pierce-Endogen). Protein samples (50 μg) were dena-
tured in a gel-loading buffer (Bio-Rad Laboratories) at
100°C for 5 min and then loaded onto 12% Bis-Tris
polyacrylamide gels (Bio-Rad Laboratories). Following
electrophoresis, proteins were transferred to polyvinylo-
dene difluoride membranes (Bio-Rad Laboratories) and
incubated with primary antibodies for Ship-1 (Santa
Cruz, sc8425), Tollip (AbCam, Ab37155), p105 (Santa
Cruz, sc7178), or b-Actin (Santa Cruz, sc1616R) at 4°C
overnight. Membranes were then incubated with horse-
radish peroxidase conjugated anti-rabbit, anti-goat, or
anti-mouse antibody (Santa Cruz Biotechnology) and
detected by chemiluminescence (NEN Life Science Pro-
ducts) and exposed to Kodak film (Biomax). Images
were captured using an Epson scanner and the densito-
metry of the gel bands, including b-Actin loading con-
trol, was analyzed using ImageJ (NIH).
Electrophoretic Mobility Shift Assay (EMSA)
Nuclear protein extracts (n = 4 mice/treatment/time-
point) were prepared from tissue dissected from the
ipsilateral cortex. Homogenized tissue was incubated in
Buffer A (10 mM Hepes-KOH pH7.9, 60 mM KCl, 1
mM EDTA, 1 mM DTT, 1 mM PMSF) for 5 min on ice
and centrifuged at 3000 rpm for 5 min at 4°C. The pel-
lets were washed in Buffer B (10 mM Hepes-KOH
pH7.9, 60 mM KCl, 1 mM EDTA, 0.5% NP-40, 1 mM
DTT, 1 mM PMSF), resuspended in Buffer C (250 mM
Tris pH7.8, 60 mM KCl, 1 mM DTT, 1 mM PMSF),
and freeze-thawed 3 times in liquid nitrogen. All buffers
contained a protease inhibitor cocktail (Roche). After
centrifuging at 10,000 rpm for 10 min at 4°C, the super-
natant was collected and stored as nuclear extract at
-80°C. Nuclear protein concentrations were determined
using the BCA method (Pierce-Endogen). EMSAs were
performed using the Promega Gel Shift Assay System
according to the manufacturer’s instructions. Briefly, 15
μg of nuclear protein was incubated with
32P-labeled
NFB consensus oligonucleotide (Promega), either with
or without unlabeled competitor oligonucleotide, unla-
beled noncompetitor oligonucleotide, or anti-p65 anti-
body (Santa Cruz). Samples were electrophoresed on a
4% acrylamide gel, dried and exposed to phosphorima-
ger overnight. The densitometry of the gel bands was
analyzed using scanning integrated optical density soft-
ware (ImageJ).
IRF3 Activity Assay
Nuclear protein (n ≥ 4 mice/treatment/timepoint) was
isolated from fresh cortical tissue at 72 hr post injection
and from ipsilateral cortices at 3 or 24 hr following
MCAO using a Nuclear Extraction Kit (Active Motif,
Inc.). IRF3 activity was measured using 10 μgo fn u c l e a r
p r o t e i ni na nI R F 3a c t i v i t yE L I S A( A c t i v eM o t i f ,I n c ) ,
that utilizes colorimetric detection of active IRF3 bound
to immobilized oligonucleotides.
Cytokine Analysis
Cytokine/chemokine analysis for IL1b,I L 1 a,M I P - 1 a,
MCP-1, RANTES, and IL10 was performed on plasma
samples (n ≥ 3 mice/treatment/timepoint) using a multi-
plex ELISA (Quansys). An IFNb ELISA (PBL Interferon
Source) was used to measure plasma levels of IFNb.
Statistical Analysis
Data is represented as mean ± SEM. The n for each
experiment is greater than or equal to 3, as specified in
each figure. Statistical analysis was performed using
GraphPad Prism5 software. Two-way ANOVA with
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lized as specified. Significance was determined as p <
0.05.
Results
LPS preconditioning does not affect inflammatory gene
expression in the brain following stroke
We used gene microarray analysis to elucidate the pat-
tern of inflammatory or anti-inflammatory/type I IFN
gene expression in the brain following stroke. In the set-
ting of stroke, LPS preconditioned animals exhibited
regulation of a number of genes typically found down-
stream of TLR signaling. The inflammatory profile
reveals that the gene regulation is similar at each time-
point following stroke in LPS or saline preconditioned
animals (Figure 1, Rt.). There is no evidence of inflam-
matory gene expression present immediately prior to
stroke (Figure 1, Rt. 0 hr). At 3 hr post MCAO, several
inflammatory genes are upregulated including IL6, IL1b,
Ptgs2/COX2, and CCL2/MCP-1 (Figure 1, Rt.) and this
upregulation is sustained at the 24 hr timepoint follow-
ing MCAO (Figure 1, Rt.). TNFa, which is commonly
shown to be upregulated following MCAO [25,26], only
shows marginal levels of upregulation in LPS or saline
preconditioned mice (Figure 1, Rt.). To confirm the
microarray results, a subset of selected inflammatory
genes including IL6, IL1b, COX2, and TNFa, were ana-
lyzed using qtPCR. Each of these genes were upregu-
lated following MCAO in LPS and saline preconditioned
mice, but there were no significant differences based on
treatment at 3 hr (data not shown) and 24 hr (Figure 2)
following MCAO.
LPS preconditioning upregulates anti-inflammatory/type I
IFN gene expression in the brain following MCAO
Although pro-inflammatory gene expression was not dif-
ferentially modulated in preconditioned animals, micro-
array results revealed that the majority of the anti-
inflammatory/type I IFN genes, such as TGFb,I L 1
receptor antagonist (IL1rn), RANTES, and IRF7, were
upregulated following stroke in the brains of LPS versus
saline preconditioned mice (Figure 1, Lt.). IL10 gene
expression was not detected at any timepoint (Figure 1,
Lt.). TGFb, IL10, RANTES, and IFIT1 were selected for
qtPCR analysis. TGFb, RANTES, and IFIT1 were signifi-
cantly upregulated in the LPS-preconditioned brain
compared to saline 24 hr following stroke (Figure 2).
RANTES was also significantly upregulated at 3 hr fol-
lowing stroke in LPS-preconditioned mice compared to
saline (data not shown). IL10 expression remained unde-
tectable by qtPCR analysis (Figure 2), suggesting that
IL10 mRNA is not present at these timepoints in the
brain following stroke. These qtPCR results confirm the
gene expression profile observed on the microarray.
Taken together, these data indicate an enhanced anti-
inflammatory/type I IFN gene expression profile in the
brain of LPS-preconditioned animals following MCAO
while the inflammatory gene expression is unaffected.
NFB activity is suppressed in the brain of LPS-
preconditioned animals 24 hr post MCAO
NFB activity is associated with damage and inflamma-
tion in the brain that occurs in response to stroke. We
used EMSAs to evaluate the activity of the NFB subu-
nit p65 in the brain following stroke. The results indi-
cated that LPS and saline preconditioned mice have
comparable NFB activity at 3 hr post MCAO (Figure
3A). However, at 24 hr post MCAO, LPS-precondi-
tioned animals have significantly suppressed NFB activ-
ity compared to saline preconditioned mice (Figure 3A).
Ship1 and Tollip are cytosolic molecules that inhibit
TLR signaling, which leads to the suppression of NFB
a c t i v i t y .W ef o u n dt h a tS h i p 1a n dT o l l i pm R N Aa r e
upregulated in the brain 72 hr post injection versus sal-
ine controls (2.06 ± 0.27 and 2.31 ± 0.35, respectively)
but not at 3 hr post stroke (1.09 ± 0.10 and 1.05 ± 0.09,
respectively). However, by 24 hr post MCAO, Ship1 and
Tollip mRNA are significantly enhanced in the brain of
LPS-preconditioned mice compared to saline controls
(2.62 ± 0.84 and 4.01 ± 1.06, respectively, Figure 3B).
Ship1 protein is not upregulated at 72 hr post injection
(Fold change vs. saline: 1.01 ± 0.32), but becomes signif-
icantly enhanced in LPS-preconditioned mice at 3 hr
( F o l dc h a n g ev ss a l i n e :1 . 8 3±0 . 1 3 )a n da t2 4h r( F o l d
Figure 2 Enhanced anti-inflammatory/type I IFN gene
expression but comparable pro-inflammatory gene expression
in LPS-preconditioned mice post MCAO. Gene regulation 24 hr
post MCAO measured by qtPCR reveals that anti-inflammatory/type
I IFN-associated genes TGFb, RANTES, and IFIT1 are significantly
upregulated in LPS preconditioned mice compared to saline. Pro-
inflammatory genes IL6, IL1b, COX2, and TNFa show similar
regulation in LPS and saline preconditioned mice. These results
confirm the gene microarray data. Samples from mice receiving a
45 (LPS: 0.2 mg/kg) or 60 min (LPS: 0.8 mg/kg) MCAO were
combined due to comparable gene regulation (see methods). ND =
not detected. Student’s t-test, LPS vs. saline 24 hr post MCAO, **p <
0.01, n ≥ 4 per treatment.
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Tollip protein is not affected by LPS preconditioning at
72 hr post injection or 3 hr post MCAO (Fold change
vs. saline: 1.42 ± 0.10 and 0.83 ± 0.10, respectively), but
it is significantly enhanced in LPS-preconditioned mice
compared to saline controls at 24 hr post MCAO (Fold
change vs. saline: 2.42 ± 0.20, Figure 3C). Additionally,
the p50 precursor protein p105, which inhibits NFB
activity by acting like an IB molecule by sequestering
NFB in the cytosol [27,28], was significantly upregu-
l a t e d2 4h rp o s ts t r o k ei nL P S - p r e c o n d i t i o n e dm i c e
compared to saline (Figure 3D). Thus, despite the upre-
gulation of inflammatory genes, the activity of NFBi s
suppressed in the late-phase of the neuroprotective
response of LPS-preconditioned mice.
IRF3 activity in the brain is enhanced following MCAO in
LPS-preconditioned mice
IRF3 activation downstream of TLR4 is associated with
anti-inflammatory/type I IFN responses. Using an IRF3
activity ELISA, we determined that IRF3 activity is com-
parable immediately prior to stroke (data not shown)
and subsequently enhanced in the brains of LPS-precon-
ditioned mice following MCAO (Figure 4). The trend
for increased IRF3 activity is present at 3 hr post
MCAO and is significantly increased at 24 hr in LPS-
Figure 3 NFB is suppressed 24 hr post MCAO in LPS-preconditioned mice. (A) Nuclear protein obtained from ipsilateral cortices was used
to measure p65 activity by EMSA analysis. EMSA gel of pooled samples (n = 4) following 45 min MCAO for saline and LPS preconditioned (0.8
mg/kg) mice (Lt.). Quantification of band intensity of individual mice following MCAO (Rt.). NFB is significantly decreased in LPS-preconditioned
mice 24 hr post MCAO compared to saline. Supershift assay confirmed specificity for p65 oligos (data not shown). (B) Ship1 and Tollip mRNA are
significantly upregulated 24 hr post 60 minute MCAO in LPS-preconditioned (0.8 mg/kg) mice compared to saline, n ≥ 4 per treatment/
timepoint. (C) Western blot for Ship1 and Tollip and relative band quantification showing significant upregulation of Ship1 and Tollip protein 24
hr post 45 min MCAO in LPS-preconditioned mice (0.8 mg/kg), n ≥ 3 per treatment/timepoint. (D) Western blot and relative band quantification
for p105 at 24 hr post 45 minute MCAO showing significant upregulation in LPS-preconditioned (0.8 mg/kg) mice, n ≥ 3 per treatment/
timepoint. (A) Two-Way ANOVA, Bonferroni Post Hoc, *p < 0.05. (B-D) Student’s t-test, LPS vs. saline, **p < 0.01.
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showed no evidence of increased IRF3 activity following
stroke (Figure 4). This indicates that LPS precondition-
ing alters the response to ischemic injury by activating
IRF3–a finding that is consistent with the enhanced
anti-inflammatory/type I IFN gene expression.
Blood cytokine/chemokine levels parallel the expression
in the brain
Evidence indicates that stroke alters the cytokine profile
in the plasma of circulating blood [5,29]. To determine
whether LPS preconditioning changes the balance of pro-
and anti-inflammatory cytokines and chemokines in the
plasma we examined the levels of seven molecules using
ELISAs. The results indicate that the level of pro-inflam-
matory cytokines, such as IL6, IL1b,a n dM C P - 1 ,a r e
increased in both LPS and saline preconditioned mice
(Figure 5). The pro-inflammatory cytokines MIP-1a and
IL1a were not detected in the serum (data not shown).
The anti-inflammatory cytokine IL10 was significantly
increased only in the plasma of LPS-preconditioned mice
compared to saline preconditioned mice following stroke
(Figure 5). RANTES, which is a chemokine associated
with IRF3 and IRF7 activity [30], was present in the
blood of LPS-preconditioned mice at significantly greater
levels than saline preconditioned mice (Figure 5). IFNb
was not detectable in the blood of LPS or saline precon-
ditioned animals following stroke (data not shown).
Overall, this suggests that the pro-inflammatory and
anti-inflammatory/type I IFN-associated response in the
blood parallels the response in the brain following stroke.
TRIF dependent LPS preconditioning induced
neuroprotection
Evidence presented here and previously suggests that sig-
naling following stroke is redirected towards IRF3
[13,14]. TLR4 signaling, which activates IRF3, is initiated
by the adaptor molecule TRIF, while TLR4 signaling that
activates NFB is initiated by the adaptor molecule
MyD88. The individual roles of these adaptor molecules
in neuroprotection induced by LPS preconditioning are
unknown. To test whether either of these key molecular
adaptors were important in mediating the neuroprotec-
tive effects of LPS, we exposed MyD88-/- and TRIF-/-
mice to LPS preconditioning (n = 4-10 mice/treatment).
We found that MyD88-/- mice preconditioned with LPS
had significantly reduced infarct sizes in response to
MCAO compared to saline controls (Figure 6), indicating
that LPS preconditioning is able to induce neuroprotec-
tion in mice lacking MyD88. In contrast, TRIF-/- mice
preconditioned with LPS or saline had comparable infarct
sizes (Figure 6), indicating that LPS preconditioning is
not able to induce neuroprotection in mice lacking TRIF.
Importantly, the TRIF adaptor is responsible for activa-
tion of IRF3, thus, our finding that TRIF is required for
LPS preconditioning provides further support for a pro-
tective role of IRF3 activity in neuroprotection.
Discussion
Here we sought to describe the LPS-induced repro-
grammed response to stroke and to determine the
important signaling events involved in neuroprotection
against ischemic injury. Our results demonstrated that
NFB activity was suppressed and that the cytosolic
inhibitors of NFB, Ship1, Tollip, and p105, were pre-
sent 24 hr post MCAO although pro-inflammatory gene
expression was unaffected (diagrammed in Figure 7).
Interestingly, there is evidence that suppression of NFB
can promote protection against cerebral ischemia with-
out influencing pro-inflammatory cytokine production
[3,31]. In particular, administration of the NFB inhibi-
tor Tat-NEMO Binding Domain provided protection
against hypoxia-ischemia in neonatal rats without affect-
ing TNFa or IL1b production [3]. Furthermore, TLR4
deficient mice have smaller infarcts in response to
MCAO, yet the production of TNFa and IL1b was unaf-
fected [6]. This suggests that reduced ischemic injury
can be achieved by suppressing NFB activity without
suppressing pro-inflammatory cytokines and that TLR4
signaling and NFBa c t i v a t i o ni sn o tt h es o l es o u r c eo f
these pro-inflammatory cytokines in response to
ischemic injury, implicating other signaling cascades and
transcription factors in the inflammatory response.
Thus, consistent with our result, reprogramming the
TLR4 response would not alter inflammatory gene
expression in the brain.
Figure 4 IRF3 activity is enhanced following MCAO in LPS-
preconditioned mice. Nuclear protein obtained from ipsilateral
cortex post 60 min MCAO analyzed using an IRF3 activity ELISA
(Active Motif, Inc.) revealed a significant increase in IRF3 activity in
LPS-preconditioned (0.8 mg/kg) mice. Two-way ANOVA, Bonferroni
Post Hoc, LPS vs. saline, *p < 0.05, n ≥ 4 per treatment.
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ischemic injury; however, investigation into the role of
NFB activity has revealed conflicting results [2]. For
instance, NFB is constitutively active in neurons, a
requirement for their survival, while the surrounding
glial cells have inducible NFB activity [32]. In response
to ischemic challenge, NFB activity in astrocytes is
responsible for detrimental inflammation [33]. This
concept of pleotropic roles also applies to many of the
inflammatory genes expressed in the brain in the setting
of stroke [34,35]. For example, intracerebroventricular
injection of recombinant IL6 significantly decreased the
infarct size in rats 24 hr post MCAO [36]. IL1b is a
potent inducer of IL1 receptor antagonist (IL-rn), which
significantly reduces damage in response to stroke [37]
and, notably, is upregulated in our microarray (Figure 1,
Lt.). TNFa is considered to play multiple roles in stroke
injury mediating many neuroprotective and injurious
effects [34]. Furthermore, in response to viral challenge,
the simultaneous presence of inflammatory cytokines,
such as TNFa, and type I IFNs can alter their effects
and synergize to promote a more protective state [38].
Thus, alterations in the environment in which NFBi s
activated and inflammatory genes are present may affect
the roles pro-inflammatory mediators play in injury and
may even contribute to the protective phenotype.
IRF3 activity induces the expression of anti-inflamma-
tory and type I IFN-associated genes. Interestingly, mice
deficient in IRF3 are not protected against cerebral
ischemia by LPS preconditioning [13]. We have further
established the importance of IRF3 in neuroprotection
by identifying that multiple preconditioning paradigms
including LPS, CpG (TLR9 agonist) and brief ischemia
induce a common set of IRF-mediated genes in the
Figure 6 LPS preconditioning requires TLR signaling through
TRIF to promote neuroprotection. WT, MyD88-/-, and TRIF-/- mice
were preconditioned with LPS (0.8 mg/kg) 3 days prior to 40 min
MCAO. MyD88-/- mice were protected by LPS preconditioning
resulting in smaller infarct sizes. TRIF-/- mice did not have reduced
infarct sizes, demonstrating that TRIF deficient mice are not
protected by LPS preconditioning. Thus, TRIF is required for LPS
preconditioning induced neuroprotection. Student’s t-test, LPS vs.
saline, *p < 0.05, n = 4-10 per treatment.
Figure 5 Blood cytokine/chemokine levels show alterations in gene expression patterns comparable to the brain. Plasma collected from
saline or LPS-preconditioned (0.8 mg/kg) mice at the time of or following 60 min MCAO was examined using a multikine ELISA (Quansys).
Results indicated that pro-inflammatory cytokines IL1b, IL6 and MCP-1 are similar in saline and LPS-preconditioned mice. In contrast, LPS-
preconditioned mice have significantly enhanced levels of the anti-inflammatory/type I IFN-associated cytokine and chemokine IL10 and RANTES
compared to saline following MCAO. Two-way ANOVA, LPS vs. saline, *p < 0.05, n ≥ 3 per treatment.
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Here we demonstrate that IRF3 activity is upregulated
in the brain of LPS-preconditioned mice in response to
MCAO and that several IRF3-mediated genes are also
upregulated, including RANTES and IFIT1 (diagrammed
in Figure 7), which may mitigate the damaging effects of
ischemia.
Many of the upregulated anti-inflammatory/type I IFN
genes in the brain following stroke have several identi-
fied neuroprotective functions. TGFb has been shown to
protect neurons from apoptosis, promote angiogenesis,
decrease microglial activation, and reduce edema
[34,39]. RANTES, which is induced by IRF3 and IRF7
[30], has been shown to protect neurons from cell death
in response to HIV-1 glycoprotein gp120 [40]. In the
setting of brain ischemia, mice deficient in the RANTES
receptor, CCR5, have larger infarcts, suggesting a neuro-
protective role for CCR5 activation [41]. Notably, the
expression of CCR5 is upregulated in our microarray
data (Figure 1, Lt). IFIT1 is commonly associated with
IRF3 signaling in response to IFN treatment and viral
infection [42]. Little is known about a role for IFIT1 in
ischemic injury; however, it is inducible in microglia and
neurons and has been shown to affect NFBa n dI R F 3
activation [42-45]. Additional anti-inflammatory/type I
IFN genes shown to be upregulated in our microarray
studies have potential roles in neuroprotection including
IL-receptor antagonist (IL-rn), which is associated with
reduced infarct size in response to stroke [34,46]. A
r e c o m b i n a n tf o r mo fI L - r ni sb e i n gt e s t e di nP h a s eI I
Figure 7 Schematic of TLR4 signaling and gene expression following stroke. (Top) TLR4 signaling cascades following stroke. In the
absence of LPS preconditioning, stroke leads to NFB activation without IRF3 activation. LPS preconditioning prior to stroke leads to robust
activation of IRF3 and suppressed NFB activity compared to stroke alone. (Bottom) Gene expression 24 hr post stroke. Stroke alone
dramatically upregulates pro-inflammatory genes. LPS preconditioning prior to stroke dramatically upregulates anti-inflammatory/Type I IFN
genes, many of which are associated with IRF3, while still maintaining a pro-inflammatory response.
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Although not detected in our gene microarray studies
here, perhaps due to assay sensitivity for IFNb transcript
on the microarray, we have previously published that
IFNb mRNA, a type I IFN known to have neuroprotec-
tive properties, is upregulated following stroke in the
brain of LPS-preconditioned mice using qtPCR [13].
T h ep r o t e c t i v ef u n c t i o n so ft h e s eg e n e sm a yb eo fc o n -
siderable importance to the neuroprotective phenotype
following MCAO induced by LPS preconditioning.
Research strongly suggests that cerebral ischemia dra-
matically alters the protein and gene expression profile
in the peripheral blood [5,29,49,50]. Our results demon-
s t r a t et h a tt h ec y t o k i n ea n dc h e m o k i n er e s p o n s ei nt h e
blood paralleled the pattern of gene expression in the
brain. Overall, inflammatory cytokine protein levels
were similarly induced in LPS and saline preconditioned
mice following stroke. However, we have previously
p u b l i s h e dt h a tT N F a is significantly reduced in the
plasma of LPS-preconditioned mice following MCAO
[51]. The anti-inflammatory and type I IFN-induced
cytokines and chemokines measured in the blood were
enhanced in LPS-preconditioned mice compared to sal-
ine. In particular, IL10 was significantly upregulated in
the blood following MCAO of LPS-preconditioned mice.
Importantly, in humans, upregulation of IL10 in the
blood has been correlated with improved outcome in
stroke [52]. While IL10 mRNA was not detectable in
the brain, IL10 can be induced by IRF3 activity and
therefore is indicative of the same redirected response
seen in the brain. IFNb was not detected in the blood
24 hr post MCAO. This may be due to the kinetics of
IFNb expression. Further investigation into the time
course of IFNb induction in the blood is necessary to
fully understand the role of IFNb in this system. The
redirected signaling observed in the blood may stem
from the brain’s response to injury by leaking proteins
into the peripheral circulation; however, this is not con-
sidered a major source of plasma cytokines at these
early timepoints following stroke [29]. Alternately,
because LPS administration occurs by a systemic route,
target cells in the periphery may become tolerant to
activation by the secondary stimuli resulting from
ischemic injury. Although our data does not distinguish
between these possibilities, it is clear that LPS precondi-
tioning alters the response to injury in the brain and the
blood in a manner that promotes a protective
phenotype.
TLR4 signals through the adaptor molecules MyD88
and TRIF. MyD88 signaling culminates in NFBa c t i v a -
tion. TRIF signaling can activate both IRF3 and NFB,
although IRF3 activation often is more rapid and robust,
while activation of NFB is a secondary effect that
occurs as part of late-phase TLR signaling [53]. The
data presented in this paper and Marsh et al., 2009 [13]
suggests a dominant role for IRF3 signaling in LPS-
induced neuroprotection, which implicates the TRIF
adaptor as a key player in the reprogrammed TLR4
response to stroke. Support for this lies in our finding
that mice deficient in TRIF are not protected by LPS
preconditioning. In contrast, MyD88 deficient mice pre-
conditioned with LPS are still protected against MCAO.
Taken together, these data strongly support a protective
role for TRIF-mediated IRF3 activation in the neuropro-
tective phenotype induced by LPS preconditioning.
TLRs have the ability to self regulate in a manner that
redirects their signaling. The classic example is endo-
toxin tolerance, whereby a low dose of the TLR4 ligand
LPS reprograms TLR4 signaling in response to a subse-
quent toxic dose of LPS, leading to a protective pheno-
type [54]. This reprogrammed response comes in two
major forms: (1.) suppressed pro-inflammatory signaling
and enhanced anti-inflammatory/type I IFN signaling, or
(2.) enhanced anti-inflammatory/type I IFN signaling in
the absence of suppressed pro-inflammatory signaling.
Thus, the suppressed NFB activity, the enhanced IRF3
activity, and the upregulated anti-inflammatory/type I
IFN associated genes seen in the LPS-preconditioned
brain following stroke is reminiscent of endotoxin toler-
ance–a phenomenon that has been best described in
macrophages in vitro, but more recently in animals.
Many other key features of endotoxin tolerance are seen
in the reprogrammed response to stroke produced by
LPS preconditioning. For example, Tollip and Ship1 are
known to be induced in endotoxin tolerance and lead to
suppressed NFB activity. TGFb has been shown to play
an important role in endotoxin tolerance, whereby
TGFb-mediated induction of SMAD4 is required to pro-
mote complete endotoxin tolerance and to induce the
NFB inhibitor, Ship1 [55]. Interestingly, in our system
the upregulation of TGFb corresponds to Ship1 upregu-
lation 24 hr post MCAO in LPS-preconditioned mice
compared to saline. Furthermore, cells deficient in TRIF
or IRF3 are unable to develop tolerance to endotoxin
[56]. This is similar to TRIF deficient or IRF3 deficient
mice not being protected by LPS preconditioning
against cerebral ischemia. Taken together, this suggests
that the cellular phenomenon of endotoxin tolerance is
potentially the same response observed in LPS precondi-
tioning wherein LPS exposure leads to a reprogrammed
TLR signaling response in the brain following stroke to
produce protection.
Conclusions
The findings reported here provide an important char-
acterization of the LPS-induced neuroprotective
response following stroke. We show that LPS precondi-
tioning induces a reprogrammed response to stroke,
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enhanced, and anti-inflammatory/type-I IFN genes are
upregulated (diagrammed in Figure 7). Interestingly, the
suppression of pro-inflammatory genes is not a neces-
sary part of the neuroprotective response induced by
LPS preconditioning. Further evaluation into the TLR4
signaling cascades revealed a seminal role for the TRIF
cascade in producing the neuroprotection initiated by
LPS preconditioning. As TRIF signaling culminates in
IRF3 activation, this finding provides further evidence
for the importance of IRF3 in the neuroprotective
response to stroke.
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